Ranirestat
As of the edition of 20 October 2026, Ranirestat is a small molecule: went quiet in 2013; acts on AKR1B1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2013
- Kind
- Small molecule
- Registered trials
- 2, 0 stopped early
- Disease areas
- Hormones; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Ranirestat.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AKR1B1 | Aldo-keto reductase family 1 member B1 | P15121 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 2 | 2 | 0 | 0 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sumitomo Pharma | Lead sponsor of trials | 2004 to now |
| Eisai | Lead sponsor of trials | 2009 to now |